In Phase 2 Trial, Daxdilimab Reduces Disease Activity in Moderate-to-Severe Discoid Lupus

The IgG1 monoclonal antibody daxdilimab was associated with a significant drop in disease activity, with a favorable safety profile in patients with moderate-to-severe discoid lupus erythematosus.

from Ob/Gyn & Women’s Health – Medscape https://www.medscape.com/viewarticle/phase-2-trial-daxdilimab-reduces-disease-activity-moderate-2026a10010wt
via IFTTT

AAO 2026 Preview: Emerging Therapies for Wet AMD

Anticipated presentations on emerging wet AMD treatment strategies, including TKI, gene therapy, and individualized anti-VEGF therapy.

from Ob/Gyn & Women’s Health – Medscape https://www.medscape.com/viewarticle/mdangle-aao-2026-wet-amd-preview-2026a1000xox
via IFTTT

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

A Trump administration rule to cut hospital drug prices for Medicare patients ⁠may apply to as few as four drugmakers after exempting companies that signed separate “most…

from Ob/Gyn & Women’s Health – Medscape https://www.medscape.com/s/viewarticle/trump-medicare-drug-pricing-model-may-apply-only-four-2026a10010tb
via IFTTT

UnitedHealthcare, Aetna Say 2027 Medicare Advantage Plans to Offer More Limited Provider Networks

US health insurers including UnitedHealthcare and CVS Health’s Aetna will shift to offer more Medicare Advantage plans that limit provider access for ⁠enrolled users, the…

from Ob/Gyn & Women’s Health – Medscape https://www.medscape.com/s/viewarticle/unitedhealthcare-aetna-say-2027-medicare-advantage-plans-2026a10010sf
via IFTTT

robotic surgeon, gynecologic cancer treatment center, holistic oncologist

Design a site like this with WordPress.com
Get started